One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Mirtazapine as Appetite Stimulant in Patients With Non–Small Cell Lung Cancer and Anorexia
Oscar Arrieta, MD, MSc1; Daniela Cárdenas-Fernández, BSD2; Oscar Rodriguez-Mayoral, MD3; Salvador Gutierrez-Torres, MD4; Diana Castañares, MD1; Diana Flores-Estrada, SW1; Edgar Reyes, MD1; Dennis López, MD1; Pablo Barragán, MD1; Pamela Soberanis Pina, MD1; Andres F. Cardona, MD, MSc, PhD5; Jenny G. Turcott, MSc, PhD2
doi : 10.1001/jamaoncol.2023.5232
March 2024, Vol 10, No. 3, Pages 1-416
Atezolizumab and Platinum Plus Pemetrexed With or Without Bevacizumab for Metastatic Nonsquamous Non–Small Cell Lung Cancer
Yoshimasa Shiraishi, MD1; Junji Kishimoto, MA2; Shunichi Sugawara, MD, PhD3; Hideaki Mizutani, MD, PhD4; Haruko Daga, MD, PhD5; Koichi Azuma, MD, PhD6; Hirotaka Matsumoto, MD, PhD7; Osamu Hataji, MD, PhD8; Kazumi Nishino, MD, PhD9; Masahide Mori, MD, PhD10; Takehito Shukuya, MD, PhD11; Haruhiro Saito, MD, PhD12; Motoko Tachihara, MD, PhD13; Hidetoshi Hayashi, MD, PhD14; Asuka Tsuya, MD, PhD15; Kazushige Wakuda, MD, PhD16; Noriko Yanagitani, MD, PhD17; Tomohiro Sakamoto, MD, PhD18; Satoru Miura, MD, PhD19; Akito Hata, MD20; Morihito Okada, MD, PhD21; Toshiyuki Kozuki, MD, PhD22; Yuki Sato, MD23; Taishi Harada, MD, PhD24; Koichi Takayama, MD, PhD25; Nobuyuki Yamamoto, MD, PhD26; Kazuhiko Nakagawa, MD, PhD14; Isamu Okamoto, MD, PhD1
Whole-Brain Radiotherapy Alone vs Preceded by Bevacizumab, Etoposide, and Cisplatin for Untreated Brain Metastases From Breast Cancer
Tom Wei-Wu Chen, MD, PhD1,2,3; Ming-Shen Dai, MD, PhD4; Ling-Ming Tseng, MD, PhD5; Shin-Cheh Chen, MD, PhD6; Tsu-Yi Chao, MD, PhD7,8; Ta-Chung Chao, MD, PhD9; Yuan-Ching Chang, MD, PhD10; Chang-Fang Chiu, MD, PhD11; Chien-Ting Liu, MD12; Ching-Hung Lin, MD, PhD1,3; Chun-Yu Liu, MD, PhD9; Ya-Fang Chen, MD, PhD13; Dwan-Ying Chang, MD1,3; Jyh-Cherng Yu, MD, PhD14; Kun-Ming Rau, MD, PhD15; Yao-Yu Hsieh, MD, PhD7,8; Shih-Che Shen, MD, PhD6; Shu-Min Huang, MSc1; Ann-Lii Cheng, MD, PhD1,2,3; Yen-Shen Lu, MD, PhD1,2,3
Brain Radiotherapy With Pyrotinib and Capecitabine in Patients With ERBB2-Positive Advanced Breast Cancer and Brain Metastases
Zhaozhi Yang, MD, PhD1,2,3; Jin Meng, MD, PhD1,2,3; Xin Mei, MD, PhD1,2,3; Miao Mo, MD4; Qin Xiao, MD5; Xu Han, MS1,2,3; Li Zhang, MD, PhD1,2,3; Wei Shi, MD, PhD1,2,3; Xingxing Chen, MD, PhD1; Jinli Ma, MD, PhD1,2,3; Joshua Palmer, MD6; Zhimin Shao, MD, PhD7; Zhen Zhang, MD, PhD1,2,3; Xiaoli Yu, MD, PhD1,2,3; Xiaomao Guo, MD, PhD1,2,3
Immunotherapy Initiation at the End of Life in Patients With Metastatic Cancer in the US
Daniel M. Kerekes, MD, MHS1; Alexander E. Frey, MD1; Elizabeth H. Prsic, MD2; Thuy T. Tran, MD, PhD2; James E. Clune, MD1; Mario Sznol, MD2; Harriet M. Kluger, MD2; Howard P. Forman, MD, MBA3; Robert D. Becher, MD, MS1; Kelly L. Olino, MD1; Sajid A. Khan, MD1
Accelerated Hypofractionated Chemoradiation Followed by Stereotactic Ablative Radiotherapy Boost for Locally Advanced, Unresectable Non–Small Cell Lung Cancer
Trudy C. Wu, MD1; Elaine Luterstein, MD2; Beth K. Neilsen, MD, PhD1; Jonathan W. Goldman, MD3; Edward B. Garon, MD3; Jay M. Lee, MD4; Carol Felix, BS1; Minsong Cao, PhD1; Stephen E. Tenn, PhD1; Daniel A. Low, PhD1; Patrick A. Kupelian, MD5; Michael L. Steinberg, MD1; Percy Lee, MD1,6
Endocrine-Sensitive Disease Rate in Postmenopausal Patients With Estrogen Receptor–Rich/ERBB2-Negative Breast Cancer Receiving Neoadjuvant Anastrozole, Fulvestrant, or Their Combination
Cynthia X. Ma, MD, PhD1; Vera J. Suman, PhD2; Souzan Sanati, MD3; Kiran Vij, MD1; Meenakshi Anurag, PhD4; A. Marilyn Leitch, MD5; Gary W. Unzeitig, MD6; Jeremy Hoog, BS1; Aranzazu Fernandez-Martinez, MD7; Cheng Fan, MS7; Richard A. Gibbs, PhD4; Mark A. Watson, MD, PhD1; Travis J. Dockter, MS2; Olwen Hahn, MD8; Joseph M. Guenther, MD9; Abigail Caudle, MD10; Erika Crouch, MD1; Amy Tiersten, MD11; Monica Mita, MD3; Wajeeha Razaq, MD12; Tina J. Hieken, MD13; Yang Wang, MD14; Mothaffar F. Rimawi, MD4; Anna Weiss, MD15; Eric P. Winer, MD17; Kelly K. Hunt, MD10; Charles M. Perou, PhD7; Matthew J. Ellis, MB, PhD4; Ann H. Partridge, MD16; Lisa A. Carey, MD7
Investigation of Genetic Alterations Associated With Interval Breast Cancer
Juan Rodriguez, PhD1; Felix Grassmann, PhD1,2; Qingyang Xiao, PhD1; Mikael Eriksson, MD, PhD1; Xinhe Mao, MSc1; Svetlana Bajalica-Lagercrantz, MD, PhD3; Per Hall, MD, PhD1,4; Kamila Czene, PhD1
Review of Racial and Ethnic Representation of Participants Enrolled in Pediatric Clinical Trials of Oncology Drugs Conducted Through FDA Written Requests
Lola A. Fashoyin-Aje, MD, MPH1; Alemayehu Y. Akalu, PharmD1; Jessica Boehmer, MBA1; Richard Pazdur, MD1; Martha Donoghue, MD1; Gregory H. Reaman, MD2
Substance Use Disorders Among US Adult Cancer Survivors
Katie F. Jones, PhD1; Oyomoare L. Osazuwa-Peters, PhD2; Andrea Des Marais, MPH2; Jessica S. Merlin, MD, PhD, MBA3; Devon K. Check, PhD2
Out-of-Pocket Costs and Outpatient Visits Among Patients With Cancer in High-Deductible Health Plans
Nicolas K. Trad, MD1; Fang Zhang, PhD2; James Franklin Wharam, MD, MPH3,4
Efficacy of Tixagevimab-Cilgavimab as Immunoprophylaxis in Patients With Hematologic Cancer
Marco Salvini, MD1; Paolo Antonio Grossi, MD, PhD1,2; Alessandro Cacioppo, MD2; Michele Merli, MD3; Giacomo Pellegrini, MSc1; Marco Brociner, MD1; Francesco Passamonti, MD, PhD3,4
Critical Appraisal of Guideline Recommendations on Systemic Therapies for Advanced Hepatocellular Carcinoma
Sarah Cappuyns, MD1,2; Virginia Corbett, MD1; Mark Yarchoan, MD3; Richard S. Finn, MD4; Josep M. Llovet, MD, PhD1,5,6
The Case for Allowing Proton Beam Therapy on Head and Neck Cooperative Group Studies
Neal S. McCall, MD1,2; Steven J. Frank, MD3; William A. Stokes, MD1
Examining Medicaid Waivers—An Opportunity to Promote Equity in Cancer Care
Lily J. Greene, BA1; Benjamin Carter, PhD2; Andrew P. Loehrer, MD, MPH3
Initiating Immunotherapy in the Treatment of Stage IV Cancers in the Month Before Death—A Health Care Disparities Lens
Michael Hoerger, PhD, MSCR, MBA1; Navya Nair, MD, MPH2; Sonia Malhotra, MD, MS3
Stereotactic Body Radiotherapy in Locally Advanced Non–Small Cell Lung Cancer—Is This the Future?
Nataniel H. Lester-Coll, MD1; Henry S. Park, MD, MPH2
Clinical Trials for Patients With Cancer
Fawzi Abu Rous, MD1; Aakash Desai, MD, MPH2; Eric K. Singhi, MD3
Thinking That I Had Cancer Made Me a Better Oncologist
Mary McGunigal, MD1
HIMALAYA Overall Survival Prominence and Other Routes to the Peak—Reply
Josep M. Llovet, MD, PhD1,2,3; Sarah Cappuyns, MD, PhD1,4; Richard S. Finn, MD5
Wildfire Exposure and Lung Cancer Survival
Akihiko Ozaki, MD, DrPH1; Michio Murakami, PhD2; Claire Leppold, PhD3
Wildfire Exposure and Lung Cancer Survival—Reply
Leticia M. Nogueira, PhD, MPH1; Yang Liu, PhD2
HIMALAYA Overall Survival Prominence and Other Routes to the Peak
Ghassan K. Abou-Alfa, MD, MBA1,2,3; Bruno Sangro, MD, PhD4
Unveiling an Overlooked Link—Promising Drug Efficacy in Lowering Withdrawal Rates in Cancer Trials
Michioki Endo, MD1; Akihiko Ozaki, MD, DrPH2,3; Masahiro Kami, MD, PhD3
Unveiling an Overlooked Link—Promising Drug Efficacy in Lowering Withdrawal Rates in Cancer Trials—Reply
Shauna L. Hillman, MS1; Aminah Jatoi, MD2,3; Sumithra J. Mandrekar, PhD1
